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Abstract 
 
The existence of grey matter (GM) atrophy right after the first clinical event suggestive of 
multiple sclerosis (MS) remains controversial. The aim of this study was therefore to establish 
whether regional GM atrophy is already present in the earliest stage of MS assessing regional 
GM atrophy in a large group of patients. Sixty two patients with a clinically isolated 
syndrome (CIS) were examined on a 1.5T MR imager within six months after their first 
clinical events. A group of thirty seven matched healthy control subjects were also included in 
the study. An optimized Voxel Based Morphometric (VBM) method customised for MS was 
applied on volumetric T1-weighted images. The functional status of patients was assessed 
using the Expanded Disability Status Scale (EDSS) and the Brief Repeatable Battery. VBM 
analysis (p<0.005, FWE corrected) on patients versus control subjects showed the presence of 
significant focal GM atrophy in patients involving the bilateral insula, the bilateral 
orbitofrontal cortices, the bilateral internal and inferior temporal regions, the posterior 
cingulate cortex, the bilateral thalami, the bilateral caudate nuclei, the bilateral lenticular 
nuclei, and the bilateral cerebellum. EDSS was slightly correlated (rho=-0.37 p=0.0027) with 
the atrophy of the right cerebellum. No correlations have been evidenced between the 
cognitive status of patients and the regional GM atrophy. The present study performed on a 
large group of CIS patients demonstrated that regional GM atrophy is present right after the 
first clinical event of multiple sclerosis and mainly affects the deep GM and the limbic 
system. 
Introduction 
 
Multiple sclerosis (MS) is an inflammatory disease affecting the central nervous system, 
which is frequently responsible for severe disability, mainly in the form of ambulatory 
deficits, which often develop after the disease has been evolving for several years. Grey 
Matter (GM) pathology in MS is now well recognized 1 and could be relevant to the 
understanding of the clinico-radiological dissociation in patients with MS, where the focal 
demyelination in the white matter (WM) observed in conventional MRI cannot fully explain 
the clinical status (including cognitive impairment) 1-3.  
Various studies based on whole brain or whole GM analyses have shown that particularly 
high rates of atrophy sometimes occur during the first few years of the disease in patients with 
a clinical isolated syndrome (CIS) who undergo a subsequent conversion to clinically definite 
MS, but not in patients in whom this conversion does not occur 4. Two recent studies using 
voxel based morphometry (VBM) methods on patients with CIS have yielded contradictory 
results. In the one study, which involved a relatively small sample of patients (n=28), no 
regional GM atrophy was detected 5, whereas the authors of the other study, which involved a 
larger group of patients (n=41), reported the existence of significant regional GM atrophy, 
mainly located in the deep GM 6.  
The aim of the present study was therefore to assess the levels of regional GM atrophy present 
in a large group of MS patients at the earliest stage of the disease in order to provide evidence 
for or against the existence of early GM atrophy. Secondly, it was proposed to study the 
potential links between regional GM atrophy and clinical status of patients (including 
cognitive impairment). 
  
 
Methods 
 
Subjects 
 
Sixty-two patients presenting with CIS and 37 healthy sex-age and educational level- matched 
control subjects were included in this study (Table 1). All the subjects (patients and controls) 
were right-handed (>70% Olfield scale) native French speakers. Patients were recruited at the 
Department of Neurology (University Hospital of Marseille), based on the following criteria: 
1) age between 18 and 45; 2) occurrence of the first presumed inflammatory demyelinating 
event in the central nervous system involving either the optic nerve, the spinal cord, a brain 
hemisphere or the brainstem; 3) no previous history of neurological symptoms suggestive of 
demyelination; 4)  no possible alternative diagnoses (lupus erythematosus, antiphospholipid 
antibody syndrome, Behcet disease, sarcoidosis, Lyme’s disease, cerebral arteritis, brain 
lymphoma, etc.) 5) presence of oligoclonal bands on the CSF analysis; 6) presence of two or 
more lesions  in the brain or  spinal cord, detected at the initial MRI performed before 
inclusion. The last two criteria meant that only CIS patients fulfilling at least the 
dissemination in space criteria according to McDonald 7 were recruited. According to these 
restricted criteria (especially the presence in all the patients of oligoclonal bands in the CSF 
and at least two T2 WM lesions on the brain MRI), the patients included in the present study 
presented high risk for developing MS. 
Patients underwent a clinical examination during the first neurological episode. Another 
neurological examination was performed on the day of inclusion (the same day when MRI 
was performed). All the patients’ disability levels were rated using the expanded disability 
status scale (EDSS) 8 by the same neurologist (BA) on the day of inclusion. 
Neuropsychological tests were performed on the patients using the Brief Repeatable Battery 
(BRB) 9 including the Selective Reminding Test, the Spatial Recall Test, the Symbol Digit 
Modalities Test, the Paced Auditory Serial Addition Task (3’) and the Word list generation.  
All the participants gave their informed consent to participating in this study, which was 
approved by the local Ethics Committee (Timone Hospital, Marseille, France). 
 
Brain MRI 
 
The subjects were examined on a 1.5T Magnetom Vision Plus MR Imager (Siemens, 
Erlangen, Germany). A sagittal three-dimensional MP-RAGE T1-weighted sequence (TE/TR 
= 4.7 ms/9.7 ms, flip angle 12◦, 128 contiguous slices, matrix = 2562, isotropic voxel 
1.25mm×1.25mm×1.25 mm) and transverse fast double spin echo T2-weighted images 
(TE1/TE2/TR = 15 msec/85 msec/ 2600 msec, 44 contiguous slices, thickness = 3 mm, flip 
angle = 90°, FOV = 240 mm, matrix = 2562) were acquired on all subjects. 
 
Image Processing 
 
WM Lesion load 
 
WM lesions visible on T2-weighted images were contoured by the same neurologist (BA) 
using a semi-automated method (interactive thresholding technique written on the interactive 
data language (IDL) platform; Research System, Inc.).  
WM lesion masks labelled as T1-WM lesion masks were identified by simultaneously 
viewing T1-weighted and T2-weighted images before contouring the lesions on the T1-
weighted images using the same semi-automated method (interactive thresholding technique 
written on the interactive data language (IDL) platform; Research System, Inc.). 
 
Optimized VBM 
 
The potential influence of the lesions on the results of the registration is a crucial point in 
VBM study performed in MS patients. This potential caveat is probably highly critical in 
patients with several years of disease evolution when the WM lesion load is important. 
Various methods have been proposed 10 11 to limit this effect. In the present study, to minimize 
this potential caveat, we used a modified version of the optimized VBM method 12 customised 
for MS 10, where WM lesions masks were applied to patients' scans at the end of images 
processing to remove any lesional tissue erroneously classified as grey matter. Figure 1 
describes the analysis pipeline 
Volumetric T1-weighted images were first normalized spatially (medium regularization, 
7×9×7 nonlinear basis functions) into the MNI space using the T1 anatomical template 
provided by the SPM2 program. Images were then re-sampled using an isotropic 
1.5mm×1.5mm×1.5 mm voxel. The spatial normalization algorithm preserved the voxel 
intensities (concentrations) even when region volumes were stretched by warping. After 
smoothing the images with a 12-mm Gaussian filter, a local T1 template was obtained by 
averaging the smoothed images obtained with each subject. 
Secondly, the 3D- T1-weighted volumes were normalized spatially into the MNI space using 
the local T1 template previously obtained. Segmentation of these normalized 3-D T1-weighted 
volumes was performed with each subject (SPM2). The resulting normalized GM fraction 
maps were smoothed using a 12mm Gaussian filter and averaged across all controls to obtain 
the locally optimized GM template. 
Thirdly, the 3D-T1 volumes obtained with each subject were directly segmented. The 
resulting GM fraction maps were normalized spatially using the locally optimized GM 
template. The transformation obtained for each spatial normalization was applied to the 3D 
T1-weighted volumes and the WM T1 lesion masks of each subject. Then, the normalized 3D 
T1-weighted volumes were segmented and the normalized T1 lesion masks were subtracted 
from the normalized GM fraction maps to prevent misclassification of WM lesion  
Lastly, a conservative threshold of 0.75 was applied to the resulting normalized GM fraction 
maps free of WM lesions before smoothing the images with a 12-mm FWHM Gaussian 
kernel 12.  
 
Statistical mapping analysis 
 
Between-group comparisons (patients with CIS versus controls) were performed (two-sample 
t-test, p < 0.005, k = 20, FWE corrected, SPM2) on the smoothed GM fraction maps obtained 
using the optimized method to determine the location of clusters showing significant 
differences in the GM concentrations. Coordinates of significant clusters in the MNI space 
were transformed into Talairach coordinates using a nonlinear transformation to locate these 
clusters. 
 
Results 
 
Clinical and conventional MRI findings 
 
Patients’ demographic and clinical characteristics of patients are given in Table 1. The median 
time between the clinical onset and the inclusion (the time when the MRI was performed) in 
the study was 4 months (0-6). Median age of the controls was 27 years (20-46), which did not 
differ significantly from that of the patients (p=0.94). A sub-population of 37 patients 
performed the neuropsychological testing. This sub-population did not differ significantly 
from the other patients in terms of sex, age, educational level, disease duration, T2LL or 
EDSS (Table 2). We also checked whether there existed any differences in terms of GM 
atrophy between the two groups of patients (those who underwent the neuropsychological 
tests and those who did not). These two groups were not found to differ in terms of the 
regional GM atrophy detected (p<0.005, FWE corrected). The patients’ performances were 
compared with the performances previously recorded at our laboratory in a group of 52 
healthy control subjects. The patients not differ from this control group in terms of sex, age or 
educational level (Table 2). Patients showed abnormally low performances in the Spatial 
Recall Test, the Symbol Digit Modalities Test, the Paced Auditory Serial Addition Task (3’) 
and the Word list generation (Table 2). 
Brain parenchyma fraction (BPF) was not significantly decreased (p=0.06) in patients 
(BPF=0.831; SD=0.043) compared to controls (BPF=0.847; SD=0.039). GM fraction (GMF) 
was significantly decreased (p=0.01) in patients (GMF=0.50; SD=0.045) compared to 
controls (GMF=0.52; SD=0.046). WM fraction (WMF) was not decreased (p=0.94) in 
patients (WMF= 0.33; SD=0.025) compared to controls (WMF= 0.33; SD=0.021). 
 
Patterns of regional GM atrophy at the earliest stage of MS 
 
Results are summarized in Table 3 and Figure 2. At the FWE corrected statistical threshold 
level of p<0.005, patients showed atrophy localized in the bilateral thalami, the bilateral 
caudate nuclei, the bilateral lenticular nuclei, the bilateral insula, the bilateral orbitofrontal 
cortices, the bilateral internal and inferior temporal regions, the posterior cingulate cortex and 
the bilateral cerebellum; whereas healthy controls showed no significant atrophy compared to 
patients.  
 
Correlations between conventional MRI data and regional cerebral atrophy 
 
The correlations have been assessed in the whole group of patients (n=62). The degree of 
atrophy of the thalami was found to be significantly correlated with the T2LL (right thalamus: 
rho=0.57 p=0.001; left thalamus: rho=0.48 p=0.001). In the whole group of patients (n=62), 
local GM atrophy was not correlated with global GMF. 
 
Correlations between T2LL, physical and cognitive status 
 
EDSS scores assessed in all the patients (n=62) correlated slightly with the T2LL (Rho=0.26, 
p=0.03). In the sub-population of 37 patients with neuropsychological assessment, no 
correlations were found between T2LL and abnormal neuropsychological performances 
observed in patients. 
 
Correlations between regional GM atrophy, physical and cognitive status 
 
EDSS scores assessed in all the patients (n=62) were found to be correlated with the degree of 
atrophy in the right cerebellum (Rho=-0.37 p=0.0027). In the sub-population of 37 patients 
having neuropsychological assessment, abnormal neuropsychological performances (Visuo-
spatial memory (Short-term recall), Symbol Digit Modalities Test, Paced Auditory Serial 
Addition Task (3’), Word list generation) did not significantly correlate with the level of GM 
concentration in regions prone to atrophy  
 
 
 
 
Discussion 
 
The results of the present study on a large sample of patients with CIS provide evidence that 
regional GM atrophy is present in the first clinical stage of MS and that it mainly occurs in the 
deep GM and the limbic system.  
 
Pattern of local GM atrophy in patients in the earliest stage of MS 
 
Atrophy of the deep GM has been well documented in patients with relapsing remitting 14 15 
and primary progressive 10 13 MS. In a previous study on a relatively small group of patients 
(n=15) with early relapsing remitting MS (RRMS), no regional GM atrophy was detected at 
inclusion, whereas significant bilateral atrophy of the thalami was present two years later 16. 
Apart form the thalamic atrophy, a subtle involvement of the thalamus may occur in the 
earliest stage of RRMS 6 17:  in a study on a small population of patients with CIS (n=18), 
statistical mapping analysis applied to magnetization transfer ratio data showed significant 
tissue matrix disorganization of the deep GM relative to controls (n=18) 17. Recently, a VBM 
study performed in CIS demonstrated significant regional GM atrophy mainly located in the 
thalamus 6. In the present study on a larger group of patients with CIS, GM atrophy was 
detected using the VBM method in the thalamus but also in the large majority of the deep GM 
structures.  
Regional GM atrophy has been previously reported to occur in the temporal and the frontal 
cortices in patients with RRMS 18 19. In a study using a rather elegant approach to determine 
the cortical thickness, a local GM thinning was also observed in the cingulate gyrus, insula, 
and associative cortical regions, which correlated with the patients’ neurological deficits and 
their T2 LL scores 20. However, the method used in the latter study did not make it possible to 
explore the deep GM structures and no control data were used 20. A recent MRI study on MS 
patients clearly established that the temporal lobe and the hippocampus were atrophic in 
patients with MS after several years of evolution 21. Geurts et al 22 also detected numerous 
inflammatory lesions in the hippocampus  which may underlie tissue loss and GM atrophy 
evidenced by MRI.  
The pathogenesis of early GM atrophy may involve different processes 23. First, the axonal 
impairments resulting from WM lesions may induce distal GM lesions secondary to Wallerian 
degeneration 24 or anterograde transynaptic damage 25 26. In a large cohort of patients (n=425) 
in the advanced stage of the disease, Charil et al. observed the existence of  correlations 
between cortical thickness and the total lesion load and disability in the cingulate gyrus, 
insula, and associative cortical regions: these brain regions are strongly interconnected with 
other brain regions 20.  These authors suggested that interruption of WM tracts by MS plaques 
may contribute to the development of cortical atrophy. Similar observation have been 
evidenced recently by Henry and colleagues demonstrating a link between WM lesions 
located in the thalamo-cortical tract and the level of atrophy of the thalami 27. This mechanism 
may explain the correlations observed in the present study between the T2LL and atrophy of 
the thalami, one of the most strongly connected GM regions. Another possibility is that a 
pathological process characterized by iron deposition may be involved in the inflammatory 
mechanism 28. Significant correlations have been reported to exist between the number of T2 
lesions and the abnormal iron deposition rates in the thalami 29. These latter authors suggested 
that WM lesions may disrupt the axonal iron output, which leads to the accumulation of iron 
in the deep GM 29.   
Although the atrophy of the thalami was partly associated with the T2LL, no association with 
other atrophic GM regions have been evidenced suggesting that other factors may participate 
to regional atrophy. First, it is well known that the pathology of the WM is not restricted to 
the macroscopic WM lesions. Consequently, the mechanisms described above (Wallerian 
degeneration, anterograde transynaptic damage and disruption of the axonal iron output) may 
exist in the normal-appearing white matte inducing more diffuse GM atrophy. In addition the 
assessment of the potential association between the total lesion load and the regional GM 
concentration may be sub-optimal when considering the possibility of GM damage being 
mediated through WM tracts 25. Diffusion tensor tractography may be relevant in future 
studies to better assess the potential link between lesions located in the WM tracts and remote 
GM pathology. Secondly, the limited association between WM lesions and GM atrophy may 
be related to the existence of another pathological process more restricted to the GM.  
The authors of several studies have reported the occurrence of inflammatory lesions of the 
GM in MS. These GM inflammatory processes may consist of focal GM lesions and/or 
diffuse sub-pial inflammation 30. The extension of diffuse inflammatory processes in the GM 
may be more pronounced in patients with progressive forms of the disease 30. Up to now, no 
evidence has been available as to whether some GM structures may show preferential 
susceptibility to the GM inflammatory process occurring in MS. One hypothesis is that 
atrophy – the ultimate consequence of tissue injury - may start in the GM regions which are 
most sensitive to the diffuse inflammatory process, although this process may not be 
especially prominent in these regions. Another explanation for the pattern of distribution of 
the GM atrophy observed is that the GM inflammatory process may predominate in some 
regions, resulting in significant localized GM atrophy. However, to our knowledge, no data 
are available so far which shed light on the regional pattern of distribution of the GM 
inflammatory process in MS.  
Another potential mechanism involved in GM atrophy may be represented by the pathology 
and/or loss of  glial cells which represent 60% of the GM cell count in humans 31.  
 
Relationships between regional GM atrophy and clinical status 
 
Since the population studied here consisted of patients presented with CIS, the residual EDSS 
recorded after the relapse was generally low (median 1, range 0-3.5), which meant that few 
correlations with regional GM atrophy were likely to occur. In addition, the limited 
association between brain regional GM atrophy and EDSS may be partly due to the 
characteristics of the EDSS scale particularly sensitive to spinal cord pathology not explored 
in the present study. Finally, compensatory processes known to occur from the very first stage 
of the disease onwards may limit the clinical impact of early regional GM loss. The only 
significant correlation observed, which was between the atrophy of the left cerebellum and the 
EDSS, was probably due to the fact that the cerebellum contributes importantly to movement 
control 32.  
In the present study, the cognitive performances of patients with CIS were significantly 
impaired in tasks involving working memory, attention and speed of information processing. 
Previous studies have shown the existence of similar types of cognitive impairment in patients 
with CIS  33 34.  Since all the cognitive abilities in question  depend on widely distributed brain 
networks, these deficits may have resulted from connectivity disturbances secondary to WM 
injury 35. The lack of correlation observed in the present study between cognitive impairment 
and regional GM atrophy suggests that the main pathological substrate of cognitive 
impairment in CIS patients is WM pathology. With the progression of the disease, the 
contribution of the GM injury probably increases, which would explaining the correlations 
found to exist between cognitive impairment and GM injury in patients after several years of 
disease evolution 36. In addition, in a group of patients with RRMS and SPMS, Sanfilipo et al 
37
 observed that WM and GM injury had differential effects on the patients’ cognitive 
performances.  WM injury was found to be the best predictor of mental processing speed and 
working memory, whereas GM injury corresponded to verbal memory, euphoria, and 
disinhibition. In the present study on CIS patients, the fact that the cognitive impairments 
were restricted to mental processing speed and working memory may explain the lack of 
correlation observed between the regional GM volume and the cognitive deficits. The 
characteristics of the cognitive impairments may change slightly with the progression of the 
disease. In the very first stage, isolated processing speed and working memory deficits are 
directly related to the state of the WM. After several years, other cognitive abilities such as 
verbal memory are affected, probably due to the deterioration of the GM.  
In addition, in view of the presence of the GM atrophy in the limbic and para-limbic regions, 
the main functional effect of the early GM pathology may be the emotional disturbances 
occurring at this stage in the disease. Since the patients’ emotions were not assessed in the 
present study, it was not possible to test this hypothesis.  
 
 
Conclusion 
 
The present study performed on a large group of CIS patients with very low physical and 
cognitive disability, demonstrated highly significant regional GM atrophy in the deep GM and 
the limbic system. This study emphasized for an involvement of GM by MS pathological 
process from the onset of the disease. 
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Whole group 
of Patients 
(n=62) 
Patients with 
neuropsychological 
assessment (n=37) 
Mann 
Whitney 
U test* 
Age (median) 29 (20-46) 29.5 (21-45) NS (0.94) 
Time from the 
clinical onset 
(month, 
median) 
4 (0-6) 4 (1-6) NS (0.46) 
T2LL (cm3, 
median) 
2.2 (0.1-111) 2.5 (0.1-61) NS (0.7) 
EDSS 
(median) 
1 (0-3.5) 1 (0-2) NS (0.64) 
Type of 
symptoms: 
   
Spinal cord 24 (38.7%) 16 (44.4%)  
Brainstem 16 (25.8%) 11 (30.5%)  
Optic nerve 15 (24.2%) 5 (13,9 %)  
Hemispheric 7 (11.3%) 4 (11.1%)  
Table 1. Demographic and clinical characteristics of CIS patients. 
* statistical comparison between patients with neuropsychological assessment and the whole group of 
patients 
  
 
CIS Patients with 
neuropsychological 
assessment (n=37) 
Controls (n=54) P (t-Test) 
Age (years, 
mean (SD)) 
29 (7) 28 (8) NS (p=0.9) 
Educational 
Level (years, 
mean (SD)) 
13 (3) 13 (3) NS (p=0.8) 
Selective 
Reminding Test 
   
Long Term 
Storage  
58 (10) 60 (7) NS (p=0.2) 
Consistent 
Long Term 
Retrieval  
54 (12) 55 (10) NS (p=0.5) 
Delayed 
Recall  
11 (1.4) 12 (0.8) NS (p=0.08) 
Visuo-spatial 
memory 
   
Short-term  
recall 
20 (5) 23 (5) 0.02 
Long-term 
recall 
7.4 (2.5) 8 (2) NS (p=0.12) 
Symbol Digit 
Modalities Test 
52 (10) 59 (9) 0.0008 
Paced Auditory 
Serial Addition 
Task (3’) 
40 (10) 48 (8) <0.0001 
Word list 
generation 
30 (9) 36 (10) 0.001 
 
Table 2. Regions showing significant GM atrophy in CIS patients (n=62) compared to 
controls (n=37) (p<0.005, FWE corrected). 
 Regions Side Brodmann 
areas  
Talairach 
coordinates 
T Number 
of voxels 
Caudate Right NA -16 20 5 10.6 4848 
 
Left NA 14 18 3 9.73  
Lenticular nucleus Right NA -26 6 5 6.6  
 Left NA 26 4 3 6.1  
Thalamus Right NA -14 -31 11 7.7  
 
Left NA 12 -19 16 7.3  
Amygdala Right NA 24 -6 -13 10.12  
Insula Right NA -36 2 7 5.6  
 
Left NA 42 10 7 5.7  
Cerebellum Right NA -40  -78  -15 7 1620 
 
Left NA 22 -88 -16 6.7  
Orbito-frontal cortex Left BA 47 48   38  -10 7.3 423 
   28 9 -17 7.3  
 
 BA 11 25  50  -16 5.7  
 
  18   38  -22 6.4  
 
Right BA47 -26 9 -17 7.7 297 
 
 BA 11 -32   44  -12 7.4  
 
  -12   40  -20 7  
Hippocampus Right NA -28 -18 -11 7.5 287 
 
  -32 -29 -5 7  
 
Left NA 32 -30 -5 5.3 86 
Posterior cingulate 
cortex 
 BA 31 0  -34   27 7.1 71 
Inferior temporal 
cortex 
Right BA 20 -36   -6  -38 7.5 38 
 
  -57 -21  -24 6.2  
 
Left BA 37 57  -47   -9 5.9 22 
 
 BA 20 38 -4 -40 5.4  
 
Table 3. Neuropsychological tests used and results for healthy controls and CIS patients 
 
Figure 1. Analysis pipeline of the VBM procedure 
 
 
Figure 2. Regions showing significant GM atrophy in CIS patients (n=62) compared to 
controls (n=37) (p<0.005, FWE corrected). GM atrophy was localized in the bilateral thalami, 
the bilateral caudate nuclei, the bilateral lenticular nuclei, the bilateral insula, the bilateral 
orbitofrontal cortices, the bilateral internal temporal regions, the posterior cingulate cortex 
and the bilateral cerebellum. 
 


